High-Throughput Immunopeptidomics Profiling For Drug Target Identification
- Short peptide length (typically 8-15 amino acids)
- No enzymatic digestion required, as peptides are naturally presented in vivo
- Quantitative variation reflects changes in immune recognition
- Applicable to the prediction and validation of CD8⁺ and CD4⁺ T cell epitopes
- Optimized HLA peptide enrichment workflows with validated antibodies, compatible with diverse sample types
- End-to-end quality control to ensure experimental reproducibility from sample preparation to data analysis
- Flexible analytical pipelines supporting neoantigen prediction, TCR epitope identification, and off-target assessment
- Integrated multi-omics analysis combining transcriptomic and mutational data to enhance biological interpretability
Target discovery remains a central challenge in modern drug development. This is particularly evident in complex pathological contexts, including cancer, infectious diseases, and autoimmune disorders, where the accurate identification and validation of druggable targets critically determine the success of therapeutic development. In recent years, immunopeptidomics, a mass spectrometry-driven analytical approach, has emerged as a powerful strategy for drug target identification and validation.
What Is Immunopeptidomics?
Immunopeptidomics is an omics-based approach dedicated to the systematic characterization of peptides presented by major histocompatibility complex (MHC) molecules. It enables comprehensive profiling of peptide antigens displayed on the cell surface and recognized by T cells. These peptides directly reflect cellular physiological and pathological states, making them a highly relevant source of immunotherapeutic targets.
Compared with conventional proteomics, immunopeptidomics is characterized by several distinct features:
Technical Principles: From Antigen Isolation To Mass Spectrometric Characterization
1. Enrichment Of HLA-Peptide Complexes
Immunopeptidomics analysis begins with the immunoprecipitation of HLA class I or class II molecules using specific antibodies, enabling the enrichment of endogenously bound peptides. This step is highly sensitive to antibody performance, sample type, and enrichment conditions, and is a critical determinant of experimental success.
2. High-Resolution Mass Spectrometry Analysis
The enriched peptides are subsequently analyzed using high-sensitivity mass spectrometry platforms (e.g., Orbitrap Exploris, Fusion Lumos) without enzymatic digestion. Given their low abundance and short sequence length, accurate detection requires high instrument sensitivity, mass accuracy, and optimized data acquisition strategies.
3. Data Analysis And Epitope Prediction
Detected peptides are analyzed using immunopeptidomics-oriented databases (e.g., IEDB, NetMHCpan) for binding affinity prediction and immunogenicity assessment. Integration with transcriptomic (RNA-seq) or genomic (WES) data further enables the identification of mutation-derived neoantigens for precise target discovery.
Application Scenarios: Core Value In Drug Target Identification
1. Neoantigen Target Identification
In cancer immunotherapy, neoantigens represent highly tumor-specific targets with minimal off-target risk. Immunopeptidomics enables direct verification of whether mutant peptides are endogenously presented by HLA molecules, thereby increasing confidence in target selection.
2. Mechanistic Studies Of Autoimmune Diseases
Systematic profiling of HLA-presented peptides in patient-derived tissues or blood samples facilitates the identification of disease-associated autoantigens, providing mechanistic insights and potential targets for therapeutic intervention.
3. Viral Antigen Target Discovery
In the context of emerging viral infections (e.g., SARS-CoV-2), immunopeptidomics enables the identification of virally derived peptides presented in infected cells, supporting vaccine design and antiviral drug development.
4. Off-Target Risk Assessment Of Biotherapeutics
For advanced therapeutic modalities such as antibody-drug conjugates (ADCs) and CAR-T therapies, immunopeptidomics can be applied to evaluate potential off-target epitopes, thereby informing molecular design and reducing the risk of immune-related adverse effects.
MtoZ Biolabs: A High-Throughput Immunopeptidomics Platform
MtoZ Biolabs has established a high-sensitivity, high-throughput, and customizable immunopeptidomics platform, leveraging extensive expertise in proteomics and mass spectrometry to support drug target discovery and validation.
Key platform advantages include:
With continuous advances in mass spectrometry technologies and bioinformatics algorithms, immunopeptidomics is poised to become an indispensable tool in precision medicine. By providing direct evidence of physiologically presented peptides, it enables more reliable target identification and supports the rational design of personalized immunotherapies. Future applications will further expand through collaborations with academic and pharmaceutical partners, facilitating the translation of immunopeptidomics-driven discoveries into clinical practice.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
